NCT01640808View on ClinicalTrials.gov

Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC

PHASE3CompletedINTERVENTIONAL
Enrollment

616

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

October 31, 2016

Study Completion Date

November 30, 2016

Conditions
Hepatic Neoplasm Malignant Recurrent
Interventions
DRUG

NIK-333(peretinoin)

600mg (8 x 75mg capsules) orally, twice a day

DRUG

Placebo

Placebo (8 x Placebo capsules) orally, twice a day

Trial Locations (66)

466-0065

Nagoya

467-0001

Nagoya

277-8577

Kashiwa

790-0826

Matsuyama

820-0018

Iizuka

830-0011

Kurume

503-0864

Ōgaki

006-8555

Sapporo

060-0033

Sapporo

060-8648

Sapporo

670-0063

Himeji

650-0047

Kobe

663-8501

Nishinomiya

920-8641

Kanazawa

213-8587

Kawasaki

228-8520

Sagamihara

252-0375

Sagamihara

232-0024

Yokohama

241-0815

Yokohama

783-8505

Nankoku

701-0192

Kurashiki

563-8510

Ikeda

570-8507

Moriguchi

591-8025

Sakai

589-8511

Sayama

565-0871

Suita

350-0495

Iruma

411-8777

Sunto-gun

329-0498

Shimotsuke

113-8519

Bunkyo-ku,

113-0021

Bunkyo-ku

113-8655

Bunkyo-ku

101-8643

Chiyoda-ku

104-0045

Chuo-ku

105-8470

Minato-ku

180-8610

Musashino

143-8541

Ōta-ku

158-8531

Setagaya-ku

150-8935

Shibuya-ku

160-0023

Shinjuku-ku

750-0061

Shimonoseki

755-8505

Ube

400-8506

Kofu

260-0856

Chiba

810-8563

Fukuoka

814-0180

Fukuoka

500-8513

Gifu

501-1194

Gifu

734-8530

Hiroshima

734-8551

Hiroshima

890-8520

Kagoshima

860-0811

Kumamoto

852-8501

Nagasaki

950-1104

Niigata

700-8558

Okayama

534-0021

Osaka

537-8511

Osaka

540-0006

Osaka

543-8555

Osaka

545-8586

Osaka

879-5593

Ōita

840-8571

Saga

849-8501

Saga

770-8503

Tokushima

770-8539

Tokushima

641-8510

Wakayama

All Listed Sponsors
lead

Kowa Company, Ltd.

INDUSTRY

NCT01640808 - Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC | Biotech Hunter | Biotech Hunter